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The Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, Osaka, JapanSummary levels of IgG4 [1], massive inﬁltration of IgG4-positive plasmaIgG4 related cholangiopathy, a distinctive type of cholangitis of
unknown origin, is characterized by increased serum levels of
IgG4, massive inﬁltration of IgG4-positive plasma cells with
storiform ﬁbrosis and/or obliterative phlebitis in the thickened
bile duct wall, and good response to steroids. Patients with
IgG4-cholangiopathy are frequently associated with autoimmune
pancreatitis; IgG4-cholangiopathy is recognized as a biliary man-
ifestation of IgG4-related disease. This condition can be diagnosed
by a combination of imaging, serology, histopathology, and
steroid responsiveness; however, cholangiographic features are
often difﬁcult to differentiate from primary sclerosing cholangitis,
pancreatic cancer, or cholangiocarcinoma. The Japanese clinical
diagnostic criteria for IgG4-related sclerosing cholangitis estab-
lished in 2012 are useful in the diagnosis of IgG4-cholangiopathy.
Although the precise pathogenic mechanism remains unclear, the
development of IgG4-cholangiopathy may involve: susceptible
genetic factors, abnormal innate and acquired immunity,
decreased naïve regulatory T cells, and speciﬁc B cell responses.
Further studies on genetic backgrounds, disease speciﬁc anti-
gens, and the role of IgG4 are necessary to clarify the pathogenesis.
 2014 Published by Elsevier B.V. on behalf of the European
Association for the Study of the Liver. Open access under 
CC BY-NC-ND license.Introduction
IgG4 related cholangiopathy is a distinctive type of cholangitis of
unknown origin, which is characterized by increased serumJournal of Hepatology 20
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cholangitis.cells with storiform ﬁbrosis and/or obliterative phlebitis in the
bile duct wall and good response to steroids [1–3]. Patients with
IgG4-cholangiopathy are frequently associated with autoimmune
pancreatitis (AIP) [2,3], the concept of which was originally pro-
posed by Yoshida et al. [4], and Hamano et al. reported increased
serum levels of IgG4 in Japanese patients with AIP [1]. Now, it is
recognized as a biliary manifestation of IgG4-related disease
(IgG4-RD) [2–6]. Clinically, it is important to distinguish IgG4-
cholangiopathy from malignancy such as cholangiocarcinoma,
pancreas cancer, or a benign counterpart, PSC [2]. The organizing
committee of the ﬁrst international symposium on IgG4-RD in
2009 [6] proposed the nomenclature of ‘‘IgG4-related sclerosing
cholangitis’’ (IgG4-SC) instead of ‘‘IgG4-associated cholangitis’’
which was recommended by the European Association for the
Study of the Liver (EASL) [6]. Recently, the Japanese clinical
diagnostic criteria 2012 for IgG4-SC have been proposed,
although the pathogenic mechanisms remain unclear [2]. Here,
we introduce the current concept, diagnosis, and recent advances
in the pathogenesis of IgG4-SC.Current concept and diagnosis of IgG4-SC
Classiﬁcation of sclerosing cholangitis
Sclerosing cholangitis is classiﬁed into a primary type of
unknown origin such as PSC or IgG4-SC, and secondary type with
obvious pathogenesis (e.g., common bile duct (CBD) stone, chol-
angiocarcinoma, trauma, operation of biliary tract, congenital
biliary anatomy, corrosive cholangitis, ischemic bile duct steno-
sis, AIDS-related cholangitis, or biliary injury of intra-arterial
chemotherapy) (Table 1).Prevalence of IgG4-SC
The prevalence of IgG4-SC still remains unclear. About 80% of AIP
patients suffer complications with stenosis of the distal CBD with
wall thickness [2,3,5]. This stricture might be due to both the
thickening of bile duct and the effect of inﬂammation and/or
edema of pancreas without CBD wall thickness. Based on these
propositions, a recent Japanese national study analyzed 197 PSC
and 43 IgG4-SC patients without AIP [7]. The male/female ratio
was 106:91 (1.16:1) in PSC and 33:10 (3.3:1) in IgG4-SC and
the mean age [min–max] was 48.1 [4.0–86.3] in PSC and 69.314 vol. 61 j 690–695
Table 1. Classiﬁcation of sclerosing cholangitis.
Sclerosing cholangitis of unknown origin
Primary sclerosing cholangitis (PSC)
IgG4-related sclerosing cholangitis (IgG4-SC)
Secondary sclerosing cholangitis
Biliary lesion in AIDS patients
Cholangiocarcinoma
CBD stone
Postoperative/bile duct injury
Congenital biliary disorders
Chemical agents/drug-induced cholangitis
Ischemic biliary stenosis
Others
JOURNAL OF HEPATOLOGY[47.6–87.4] in IgG4-SC [7]. Cholangiographic classiﬁcation of
IgG4-SC (Fig. 1) according to the clinical diagnostic criteria of
IgG4-SC in 2012 [2] demonstrated that type IV, in which stric-
tures of the bile duct are detected only in the hepatic hilar lesions
similar to cholangiocarcinoma was the most common in cases of
IgG4-SC without AIP [7].
Bile duct images of IgG4-SC
Cholangiogram
Four types of the characteristic cholangiographic features of
IgG4-SC have been proposed based on the regions of strictureType 1 Type
a
Differential diagnosis
Pancreatic cancer
Bile duct cancer
Chronic pancreatitis
Primary sclero
Useful modalities
IDUS* (bile duct)
EUS-FNA** (pancreas)
Biopsy (bile duct)
Liver biopsy
Colonoscopy (
Fig. 1. Classiﬁcation of cholangiography in IgG4-related sclerosing cholangitis. The ch
of stricture as revealed by cholangiography and differential diagnosis. Type 1 IgG4-SC s
differentiated from chronic pancreatitis, pancreatic cancer, or cholangiocarcinoma. Type
and extrahepatic bile ducts, should be differentiated from PSC. Type 2 is further subdi
prestenotic dilation and Type 2b, with narrowing of the intrahepatic bile ducts without
lymphocytic and plasmacyte inﬁltration into the peripheral bile ducts. Type 3 IgG4-SC i
common bile duct. Type 4 IgG4-SC shows strictures of the bile duct only in the hilar hepat
from those of cholangiocarcinoma. ⁄IDUS, intraductal ultrasonography; ⁄⁄EUS-FNA, en
disease. Modiﬁed from Hepatobiliary Pancreat Sci. 2012;19:536–542 [2], Copyright  2
Journal of Hepatology 201(Fig. 1) [2]. Type 1 IgG4-SC shows stenosis only in the distal
CBD, which is often observed in pancreas cancer. Type 2 IgG4-
SC, in which stenosis is diffusely distributed throughout the
intrahepatic/proximal bile ducts, should be differentiated from
PSC. Type 3 and type 4 of IgG4-SC show stenosis in the hilar
hepatic bile duct similar to hepatic hilar cholangiocarcinoma.
Circular/symmetric thickening of the bile duct
Circular and symmetric thickening of the bile duct wall, smooth
outer and inner margin, and homogenous internal echo demon-
strated by abdominal ultrasonography (US), abdominal computed
tomography (CT), abdominal magnetic resonance imaging (MRI),
endoscopic ultrasonography (EUS), and intraductal ultrasonogra-
phy (IDUS) are most characteristic images of the bile duct [2].
These characteristic features are recognized not only in the
stenotic areas or occasionally in the gallbladder but also in areas
without stenosis that appear normal in a cholangiogram [2].
Characteristic hematological ﬁndings
More than 80% of the patients with IgG4-SC show elevation of
serum hepatobiliary enzymes, total bilirubin in cases of
obstructive jaundice, and serum IgG4 levels (higher than the
upper limit of normal value (ULN) of 135 mg/dl) [1,2]. However,
elevation of serum IgG4 levels is not necessarily speciﬁc to
IgG4-SC; it is also observed in atopic dermatitis, pemphigus,
asthma, and some malignant cholangio-pancreatic diseases
[2–6]. Cut-off values of serum IgG4 higher than x 2 ULN may
be useful for more precisely differentiating IgG4-SC from PSC or
cholangiocarcinoma [2,7]. 2 Type 3 Type 4
b
sing cholangitis Bile duct cancer
Gallbladder cancer
R/O co-existence of IBD***)
EUS (bile duct, pancreas)
IDUS (bile duct)
Biopsy (bile duct)
aracteristic features of IgG4-SC can be classiﬁed into 4 types based on the regions
hows stenosis only in the lower part of the common bile duct, and it should be
2 IgG4-SC, in which stenosis is diffusely distributed throughout the intrahepatic
vided into 2 types. Type 2a, with narrowing of the intrahepatic bile ducts with
prestenotic dilation and reduced bile duct branches, which is caused by marked
s characterized by stenosis in both the hilar hepatic lesions and the lower part of
ic lesions. Cholangiographic ﬁndings of type 3 and type 4 need to be discriminated
doscopic ultrasound-guided ﬁne-needle aspiration; ⁄⁄⁄IBD, inﬂammatory bowel
013, with permission.
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Other organ involvements (OOIs)
Most cases of IgG4-SC (80–90%) are associated with AIP. It is
particularly difﬁcult to accurately diagnose IgG4-SC without AIP
[3,5]. Occasionally, IgG4-SC is associated with other systemic
IgG4-RD such as IgG4-related symmetrical dacryoadenitis/sialad-
enitis and IgG4-related retroperitoneal ﬁbrosis [5,6]; these are
helpful in the diagnosis of IgG4-SC. Unlike PSC, inﬂammatory
bowel disease (IBD) is rarely observed in patients with IgG4-SC
[2,6].
Histopathological ﬁndings of bile ducts
In IgG4-SC, massive inﬁltration of IgG4-positive plasma cells, sto-
riform ﬁbrosis, and/or obliterative phlebitis in the bile duct wall
are characteristic and called lymphoplasmacytic sclerosing
cholangitis (LPSC) [2,6]. Such ﬁbroinﬂammatory involvement is
mainly observed in the submucosa of the bile duct wall, whereas
the epithelium of the bile duct is intact [8]. Endoscopic transpap-
illary bile duct biopsy or cytological examinations are useful for
differential diagnosis of cholangiocarcinoma, although it is difﬁ-
cult to take enough biopsy samples for characteristic histopathol-
ogical ﬁndings of IgG4-SC [2]. Liver biopsy is sometimes useful in
the diagnosis of IgG4-SC in cases of intrahepatic bile duct
involvement [2].
Effectiveness of steroid therapy
In contrast to PSC or cholangiocarcinoma, the most characteristic
feature of IgG4-SC is steroid responsiveness. It is important to
make efforts of ruling out malignancy and to take enough biopsy
samples. At many institutions, the therapeutic protocol for
IgG4-SC follows that for AIP, such as oral prednisolone with the
initial dose of 0.5–0.6/kg body weight/day [9]. If lesions do not
respond to steroids, re-evaluation to rule out malignancy should
be performed. In the refractory cases for oral steroids, it has been
reported that steroid mini-pulse therapy [10], immunomodula-
tors [11], and rituximab [12] are useful.
Diagnosis of IgG4-SC
In many cases of IgG4-SC, diagnosis can be made by a combina-
tion of characteristic biliary images (MRCP, ERCP, and EUS),
increased serum levels of IgG4, coexistence of other organ
involvements (OOIs), and characteristic histopathological fea-
tures; however it is sometimes difﬁcult to distinguish from PSC,
cholangiocarcinoma, and pancreas cancer [2]. Based on these
ﬁndings, the Japanese study group for IgG4-SC proposed the clin-
ical diagnostic criteria for IgG4-SC [2] (Table 2). The effectiveness
of steroid therapy is an optional diagnostic criterion to ensure
accurate diagnosis of IgG4-SC like AIP only after negative workup
of malignancy [2].Recent advances in the pathogenesis of IgG4-SC
Although the precise pathogenic mechanism remains unclear,
susceptible genetic factors, abnormal innate and acquired immu-
nity, decreased naïve regulatory T cells, and speciﬁc B cell
responses may be involved in the development of IgG4-cholangi-
opathy [5,3]. The class II antigen haplotype of the human major692 Journal of Hepatology 201histocompatibility complex (HLA-DRB1⁄0405-DQB1⁄0401), poly-
morphisms of nuclear factor-jB and Fc-receptor-like (FCRL) 3
genes expressed on B cells have been reported in the Japanese
patients with AIP [3].
Innate immunity
Recently, abnormal innate immunity has been demonstrated in
patients with IgG4-RD. Activation of NOD-2 and TLR ligands on
monocytes or basophils from patients with IgG4-related AIP
enhance IgG4 responses via B cell activating factor (BAFF) and
IL-13, although speciﬁc pathogens still remain unclear [13]. In
animal models, activation of TLR3 (polyinosinic:polycytidylic
acid) or TLR4 (LPS) can induce immune-mediated cholangitis,
pancreatitis, and sialadenitis similar to human IgG4-RD [14].
Humoral immunity
Role of IgG4 in IgG4-SC
Although the association of IgE-mediated allergy and IgG4 anti-
bodies is well known, IgG4 characteristics are still poorly under-
stood. IgG4 has non-acting characteristics for immune responses,
and is involved in a continuous process referred to as ‘Fab-arm
exchange’, which is a swapping of a heavy chain and attached
light chain (half-molecule) with a heavy-light chain pair from
another molecule; this usually results in asymmetric antibodies
with two different antigen-combining sites [3]. While these mod-
iﬁed antibodies are hetero-bivalent, they behave as monovalent
antibodies. Another aspect of IgG4 is that it mimics IgG rheuma-
toid factor (RF) activity by interacting with IgG [3]. IgG4 seems to
be associated with a pathogenic effect in a few situations. In pem-
phigus, recognition of skin autoantigens (desmogleins) by IgG4 is
at the origin of the disease process [3]. In contrast, increased
inducible-memory Tregs in the periphery and liver tissues are
positively correlated with serum levels of IgG4 [15]. In addition,
prominent inﬁltration of Tregs upregulated IL-10 in livers of the
patients with IgG4-SC [16]. These ﬁndings suggest that hyperse-
cretory IgG4 from Tregs may be a secondary phenomenon of the
development of IgG4-SC, whereas overproduction of IgG4 by
BAFF from abnormal innate immunity-related cells such as
monocytes or basophils, may be involved with development of
IgG4-SC. Further studies are necessary to clarify the role of
IgG4 in IgG4-RD.
The complement system
Patients in active stages of AIP occasionally show decreased com-
plement (C3, C4) with elevated circulating immune complex as
well as serum levels of IgG4 and the IgG4 subclass of immune
complexes. However, a recent study showed that the classical
pathway through IgG1 may be involved in activation of the
complement system rather than mannose-binding lectin or alter-
native pathways through IgG4 [17].
Autoantibodies
Some patients with IgG4-related disease have non-speciﬁc anti-
bodies such as an anti-nuclear antibody (ANA). From the view
of IgG4 function, the big mystery is whether IgG4-related disease
is an autoimmune or an allergic disease. However, the occasional
coexistence of OOIs leads us to consider that there may be
common target antigens in the involved organs, especially the
pancreas, because of high incidence. Among candidate antigens4 vol. 61 j 690–695
Table 2. The Japanese clinical diagnostic criteria 2012 for IgG4-related sclerosing cholangitis.
Diagnostic items
1. Biliary tract imaging reveals diffuse or segmental narrowing of the intrahepatic and/or extrahepatic bile duct associated with the 
tickening of the bile duct wall
2. Hematological examination shows elevated serum IgG4 concentrations (≥135 mg/dl)
3. Coexistence of autoimmune pancreatiti, IgG4-related dacryoadenitis/sialadenitis, or IgG4-related retroperitoneal fibrosis
4. Histopathological examination shows: 
a. Marked lymphocytic and plasmacyte infiltration and fibrosis
b. Infiltration of IgG4-positive plasma cells: >10 IgG4-positive plasma cells/HPF
c. Storiform fibrosis
d. Obliterative phlebitis
Option: effectiveness of steroid therapy
A specialized facility, in which detailed examinations such as endoscopic biliary biopsy and endoscopic ultrasound-guided fine needle 
aspiration (EUS-FNA) can be administered, may include in its diagnosis the effectiveness of steroid therapy, once pancreatic or biliary 
cancers have been ruled out
Diagnosis
Definite diagnosis
1. + 3.
1. + 2. + 4.a., b.
4.a., b., c.
4.a., b., d.
Probable diagnosis
1. + 2. + option
Possible diagnosis
1. + 2.
It is necessary to exclude PSC, malignant diseases such as pancreatic or biliary cancers, and secondary sclerosing cholangitis caused by 
the diseases with obvious pathogenesis. When it is difficult to differentiate from malignant conditions, a patient must not be treated with 
facile steroid therapy but should be referred to a specialized medical facility. 
Modiﬁed from Hepatobiliary Pancreat Sci. 2012;19:536–542 [2], Copyright  2012, with permission.
JOURNAL OF HEPATOLOGYpreviously reported [18], lactoferrin (LF), carbonic anhydrase
(CA)-II, CA-IV, and pancreatic secretory trypsin inhibitor (PSTI)
are distributed in the pancreas, salivary glands, biliary duct,
lungs, and renal tubules. Immunization with CA-II or LF induced
systemic lesions such as pancreatitis, sialadenitis, cholangitis,
and interstitial nephritis in the mice models similar to human
IgG4-RD [18].
Role of B cells
In addition to steroid and immune-modulators, B cell depletion
by rituximab is a useful therapeutic strategy in IgG4-RD. Interest-
ingly, rituximab reduces only the IgG4 subclass but no other sub-
classes of IgG1, IgG2, or IgG3 [19]. A recent study showed
expansion of IgG4+ B cell receptor (BCR) clones in blood and tis-
sue of patients with active IgG4-cholangiopathy, and disappear-
ance by corticosteroid treatment. These ﬁndings suggest that
speciﬁc B cell responses may have a pivotal role in the pathogen-
esis of IgG4-SC [20].
Th1 and Th2 immune balance
The effector cells in IgG4-related diseases have been poorly
understood. The CD4+ T cells differentiate from naïve T cells
(Th0) to Th1, Th2, Th17, and regulatory T (Treg) cells [3]. In the
livers of IgG4-SC patients, a Th2 type immune reaction [16] is
induced in addition to the Th1 responses [18]. Th2 cytokines
may be involved in the progression of the disease process, espe-
cially the maturation and proliferation of local B cells and
plasmacytes.Journal of Hepatology 201Regulatory T cells
Foxp3 is a member of the forkhead/winged-helix family of tran-
scriptional regulators, and functions as the master regulator in
the development and function of CD4+CD25+ regulatory T cells
(Tregs) classiﬁed as naturally occurring CD4+CD25+ Tregs
(nTregs) originating in the thymus and adaptive Tregs (aTregs)
induced in the periphery by different antigens [15]. In IgG4-
related diseases, circulatory naïve (CD45RA+) Tregs are signiﬁ-
cantly decreased in the peripheral blood, whereas memory
(CD45RA) Tregs are signiﬁcantly increased [15]. In addition,
prominent inﬁltration of Tregs with upregulation of IL-10 is
observed in the liver of IgG4-SC patients [21]. These ﬁndings sug-
gest that increased memory-Tregs in the periphery and local tis-
sues may be an inhibitory immune response against
inﬂammation, although decreased naïve Tregs may be patho-
genic. The neonatally thymectomized (nTx)-BALB/c mice with
CA-II or LF immunization and WBN/Kob rat models showed
depletion of naïve Tregs and multi-organ inﬂammation similar
to human IgG4-RD [5]. These animal models suggested that, in
addition to depletion of naïve Tregs, macrophage activation and
Th1 immune responses by CD4+/CD8+ T cells play major roles
in the initial development of organ involvement.
Our hypothesis for the pathogenesis of IgG4-SC
Based on the above ﬁndings, we propose the pathogenic mecha-
nisms in IgG4-SC/AIP outlined in Fig. 2. The basic concept is the
biphasic mechanism of ‘‘induction’’ and ‘‘progression.’’ Initially,4 vol. 61 j 690–695 693
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Fig. 2. Hypothesis for the pathogenesis of AIP and IgG4-related disease. In the central tolerance, naïve and natural regulatory T cells (Tregs) derived from the thymus
suppress autoreactive CD4 or CD8 cells in the normal state. In the IgG4-related disease, the basic concept is the biphasic mechanism of ‘‘induction’’ and ‘‘progression’’. Initial
response to antigens (LF, CA-II, CA-IV, PSTI, amylase-alpha, PBP peptide of H. pylori, etc.) might be induced by decreased naïve-Tregs. Th2 immune responses followed by
Th1 type immune response with release of proinﬂammatory cytokines (IFN-c, IL-1B, IL-2, TNF-a). In progression, Th2 type immune responses with producing IgG, IgG4 and
autoantibodies may be involved in pathophysiology. IgG4 and ﬁbrosis may be regulated by increased IL-10 and TGF-b secreted from inducible memory-Tregs, respectively.
On the other hand, activation of NOD receptor or TLRs on monocytes or basophils increases IgG4 via upregulation BAFF and IL-13. iTreg, inducible Treg; TE, effector T cell;
nTreg, natural Treg; BAFF, B cell activating factor. Modiﬁed from J Gastroenterol. 2011;46:277–288 [5], Copyright  2012, with permission.
Clinical Application of Basic Sciencedecreased naïve-Tregs may induce a Th1 immune response with
the release of pro-inﬂammatory cytokines (IFN-c, IL-1beta, IL-2,
and TNF-a) to unknown antigens such as self-antigens (LF, CA-II,
CA-IV, PSTI, and alpha-amylase) or microorganisms (Helicobacter
pylori, commensal bacteria, and viruses). Subsequently, Th2 type
immune responses may be involved in the disease progression.
Production of IgG4 may be upregulated by BAFF from monocytes
and basophils, and by IL-10 from inducible memory-Tregs. Tumor
growth factor (TGF)-beta secreted from inducible memory-Tregs
inﬁltrating into the involved organ may induce ﬁbrosis.Conclusion
In conclusion, recent advances support the concept of IgG4-SC, a
unique clinical entity as a biliary manifestation of IgG4-RD.694 Journal of Hepatology 201Although the pathogenic mechanism remains unclear, we
proposed a hypothesis of the pathogenic mechanism of IgG4-
SC. Further studies are necessary to clarify the pathogenesis
including genetic backgrounds, disease speciﬁc antigens, and
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